임상시험용 바이오리포지토리 및 아카이브 솔루션 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 제품별, 단계별, 시험/용도별, 지역별, 부문별 예측(2026-2033년)

Clinical Trial Biorepository & Archiving Solutions Market Summary

The global clinical trial biorepository and archiving solutions market size was estimated at USD 4.68 billion in 2025 and is projected to reach USD 8.98 billion by 2033, growing at a CAGR of 8.53% from 2026 to 2033. The growth of the market is mainly due to the growing number of pharmaceutical and biotechnology companies, growing disease variation and prevalence, increasing R&D investments and growth in the CRO market.

The growing number of pharmaceutical and biotechnology companies is increasing the focus on innovative drug discovery, resulting in a rising number of clinical trials. Expansion of biologics, biosimilars, personalized medicine, orphan drugs, and adaptive trial designs is driving demand for specialized biorepository and archiving solutions. Stringent regulatory requirements from ICH-GCP, FDA, and EMA mandate long-term storage of clinical data and biospecimens, while advanced technologies for sample storage, management, and retrieval are improving efficiency, reliability, and overall market growth.

In addition, increasing pharmaceutical R&D investments are driving demand for clinical trial biorepository and archiving solutions as companies seek external expertise to accelerate drug development. Besides this, major investments by global players and rising drug innovation intensify the need for secure storage, management, and retrieval of biological samples and clinical data. In addition, advanced biorepository infrastructure supports data integrity, regulatory compliance, and personalized medicine development, while encouraging new entrants and technological innovation, thereby strengthening market growth over the forecast period.

Moreover, rising prevalence of chronic and emerging diseases is increasing demand for novel therapeutics, thereby accelerating global clinical trial activity. High incidence of cardiovascular and neurological disorders, along with growing disease diversity in emerging economies, is expanding research into common and rare conditions. Besides this, larger and more diverse patient populations enable faster recruitment and support targeted and orphan drug trials. Some of the regulatory incentives for orphan diseases further boost trial volumes, increasing the need for secure biorepository and long-term archiving solutions.

Furthermore, rising R&D spending and cost-efficiency goals are driving pharmaceutical companies to outsource complex, large-scale, and decentralized clinical trials to CROs. CROs manage patient recruitment, biospecimen handling, and data operations, generating large volumes of samples and documentation. The ICH-GCP and FDA regulations govern these materials require secure, traceable, long-term storage. In addition, continued CRO expansion, multi-regional trial execution, and offshore outsourcing benefits are increasing reliance on specialized biorepository and compliant archiving solutions, supporting sustained market growth.

Global Clinical Trial Biorepository And Archiving Solutions Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical trial biorepository and archiving solutions market based on service, product, phase, trials/application and region.

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Biorepository Services
  • Warehousing & storage
  • Transportation
  • Sample Processing
  • Others
• Archiving Solution Services
  • Database Indexing and Management
  • Scanning & Destruction
  • Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical Products
• Clinical Products
  • Human Tissue
  • Organs
  • Cell Therapy
  • Stem Cell Therapy
  • Other Cell Therapy
  • Other biospecimens
• Medical Device-Generated Digital Data
• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical
• Phase I
• Phase II
• Phase III
• Phase IV
• Trials/Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug / Biopharmaceutical Trials
  • Cell Therapy Trials
  • Gene Therapy Trials
  • Others
• Medical Device Trials
• Self-Administered / Decentralized Trials
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Product
  • 1.2.3. Phase
  • 1.2.4. Trails/Application
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trial Biorepository and Archiving Solutions Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Number of Pharmaceutical and Biotechnology Companies
    • 3.2.1.2. Growing Disease Variation and Prevalence
    • 3.2.1.3. Increasing R&D Investments
    • 3.2.1.4. Growth In the CRO Market
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulations For New Drug Development
    • 3.2.2.2. Rising Cost of Clinical Trials
• 3.3. Technology Landscape
• 3.4. Pricing Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Clinical Trial Biorepository and Archiving Solutions Market: Service Estimates & Trend Analysis

• 4.1. Clinical Trial Biorepository and Archiving Solutions Market, By Service: Segment Dashboard
• 4.2. Clinical Trial Biorepository and Archiving Solutions Market, By Service: Movement Analysis
• 4.3. Clinical Trial Biorepository and Archiving Solutions Market Estimates & Forecasts, By Service, 2021 - 2033
• 4.4. Biorepository Services
  • 4.4.1. Biorepository Services Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.2. Warehousing & storage
    • 4.4.2.1. Warehousing & storage Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.3. Transportation
    • 4.4.3.1. Transportation Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.4. Sample Processing
    • 4.4.4.1. Sample Processing Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 4.5. Archiving Solution Services
  • 4.5.1. Archiving Solution Services Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.2. Database Indexing and Management
    • 4.5.2.1. Database Indexing and Management Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.3. Scanning & Destruction
    • 4.5.3.1. Scanning & Destruction Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 5. Clinical Trial Biorepository and Archiving Solutions Market: Product Estimates & Trend Analysis

• 5.1. Clinical Trial Biorepository and Archiving Solutions Market, By Product: Segment Dashboard
• 5.2. Clinical Trial Biorepository and Archiving Solutions Market, By Product: Movement Analysis
• 5.3. Clinical Trial Biorepository and Archiving Solutions Market Estimates & Forecasts, By Product, 2021 - 2033
• 5.4. Preclinical Products
  • 5.4.1. Preclinical Products Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.5. Clinical Products
  • 5.5.1. Clinical Products Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 5.5.2. Human Tissue
    • 5.5.2.1. Human Tissue Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 5.5.3. Organs
    • 5.5.3.1. Organs Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 5.5.4. Stem cells
    • 5.5.4.1. Stem Cells Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 5.5.5. Other biospecimens
    • 5.5.5.1. Other Biospecimens Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.6. Medical Device-Generated Digital Data
  • 5.6.1. Medical Device-Generated Digital Data Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 6. Clinical Trial Biorepository and Archiving Solutions Market: Phase Estimates & Trend Analysis

• 6.1. Clinical Trial Biorepository and Archiving Solutions Market, By Phase: Segment Dashboard
• 6.2. Clinical Trial Biorepository and Archiving Solutions Market, By Phase: Movement Analysis
• 6.3. Clinical Trial Biorepository and Archiving Solutions Market Estimates & Forecasts, By Phase, 2021 - 2033
• 6.4. Preclinical
  • 6.4.1. Preclinical Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.5. Phase I
  • 6.5.1. Phase I Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.6. Phase II
  • 6.6.1. Phase II Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.7. Phase III
  • 6.7.1. Phase III Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.8. Phase IV
  • 6.8.1. Phase IV Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 7. Clinical Trial Biorepository and Archiving Solutions Market: Trials/Application Estimates & Trend Analysis

• 7.1. Clinical Trial Biorepository and Archiving Solutions Market, By Trials/Application: Segment Dashboard
• 7.2. Clinical Trial Biorepository and Archiving Solutions Market, By Trials/Application: Movement Analysis
• 7.3. Clinical Trial Biorepository and Archiving Solutions Market Estimates & Forecasts, By Trials/Application, 2021 - 2033
• 7.4. Drug / Biopharmaceutical Trials
  • 7.4.1. Drug / Biopharmaceutical Trials Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.4.2. Cell Therapy Trials
    • 7.4.2.1. Cell Therapy Trials Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.4.3. Gene Therapy Trials
    • 7.4.3.1. Gene Therapy Trials Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.4.4. Others
    • 7.4.4.1. Others Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.5. Medical Device Trials
  • 7.5.1. Medical Device Trials Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.6. Self-Administered / Decentralized Trials
  • 7.6.1. Self-Administered / Decentralized Trials Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 8. Clinical Trial Biorepository and Archiving Solutions Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Medpace
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. American Type Culture Collection (ATCC)
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Cell&Co BioServices (Cryoport)
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Brooks Life Sciences (Azenta, Inc.)
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Patheon (Thermo Fisher Scientific, Inc.)
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Precision Medicine Group, LLC.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Labcorp Drug Development
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Q2 Solutions
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. LabConnect
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Charles River Laboratories
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives